Description
Pramipexole dihydrochloride monohydrate is an activator of D2DR, D3DR and D4DR. Pramipexole has been found to have neuroprotective effects independent of its dopamine receptor agonism. It reduces mitochondrial reactive oxygen species (ROS) production and inhibits the activation of apoptotic pathways.
Chemical Properties
White or almost white, crystalline powder.
Uses
Pramipexole is a drug used to treat the symptoms of Parkinson's Disease (PD) and a antidepressant. It is a non-ergot dopamine agonist drug that is efficacious in treating various Parkinson's symptoms such as tremor, rigidity, and bradykinesia (slow movement)
Definition
ChEBI: A hydrate that is the monohydrate of the dihydrochloride salt of pramiprexole.
brand name
Mirapex (Boehringer Ingelheim).
General Description
Pramipexole Dihydrochloride is a non-ergot dopamine agonist widely used for the treatment of early and advanced Parkinson′s disease (PD). It is also used to treat restless legs syndrome.
Pharmaceutical secondary standards for application in quality control, provide pharma laboratories and manufacturers with a convenient and cost-effective alternative to the preparation of in-house working standards.
Clinical Use
Parkinson’s disease
Symptomatic treatment of restless legs
Side effects
Dizziness, lightheadedness, or fainting, especially when standing up suddenly from a sitting/lying position.
drowsiness.
nausea.
seeing, hearing, or feeling things that are not there.
trouble sleeping.
twitching, twisting, or other unusual body movements.
unusual tiredness or weakness.
Drug interactions
Potentially hazardous interactions with other drugs
Avoid concomitant use with antipsychotics.
Metabolism
Pramipexole undergoes <10% metabolism to inactive
metabolites.
More than 90% of a dose is excreted via renal tubular
secretion unchanged into the urine.
